LYCOS RETRIEVER 
Chiron: Diseases
built 178 days ago
Chiron's grant to the CDC Foundation, located in Atlanta, Ga., will provide funding for an immunization program at Rabia-Balkhi Women's Hospital in Kabul, Afghanistan. Rabia-Balkhi is one of the most important centers for maternal and child healthcare in the country. In an effort to assist in rebuilding the healthcare infrastructure at the Rabia-Balkhi Women's Hospital, Chiron's grant will provide funding for a program that will provide hospital healthcare workers with the recommended adult series of immunizations, including tetanus/diphtheria, pnuemococcal, hepatitis A and B, measles/mumps/rubella, Varicella, and meningococcal. Additionally, hospital workers will be trained in administering vaccinations to patients seeking care. Overall, the program will protect not only the hospital's healthcare workers; it ... will help prevent the spread of disease in the immediate area and establish a sustainable framework for larger immunization efforts throughout the country.
Source:
Under Rutter's leadership, Chiron placed a major emphasis on detection, prevention and treatment of infectious diseases. With Merck, Chiron developed a Hepatitis B vaccine, based on the Hepatitis B pseudoparticles from yeast. Rutter's commitment to funding research on important diseases led to two of Chiron's most enduring achievements: the cloning and first sequencing of the HIV genome in 1984, and the discovery, sequencing and cloning of the hepatitis C virus in 1987.
Source:
Chiron ... has awarded a separate grant to the CDC Foundation for its International Emerging Infectious Diseases (IEID) fellowship program. The grant will provide funding for three one-year fellowships for non-U.S. doctoral-level scientists to attend the IEID laboratory training program. Each fellow will gain skills in the latest laboratory techniques and technology and thereby build the laboratory capacity for addressing diseases endemic to their home countries.
Source:
"We are pleased to have worked with InterMune to reach this agreement," said Ursula Bartels, Chiron's general counsel. "Making our HCV technology available to develop small-molecule therapeutics will help to address the toll from this terrible disease. Chiron is committed to meeting this major medical need, both through its broad licensing policy and through its own small-molecule therapeutic program."
Source:
PathoGenesis will strengthen Chiron's anti-infective development portfolio by adding pipeline candidates and substantial development skills. Chiron already has two infectious disease products in late-stage clinical development: tifacogin (tissue factor pathway inhibitor, TFPI), in Phase III trials for severe sepsis, in collaboration with Pharmacia, Inc., and recombinant human interleukin-2 (rhIL-2, or aldesleukin, marketed as Proleukin), in Phase III trials for HIV. The expanded pipeline will ... include label expansion studies for TOBI in other indications, as well as a "next generation" TOBI that is intended to shorten treatment time and improve both dosing convenience.
Source:
MORE ABOUT
Diseases